
This medication is compounded by a licensed 503A pharmacy in accordance with Section 503A of the Federal Food, Drug & Cosmetic Act, and may only be dispensed pursuant to a valid, patient-specific prescription issued by a licensed healthcare practitioner following an individualized medical evaluation. The FDA does not review or approve compounded medications, including compounded semaglutide, for safety, effectiveness, or quality. Compounded semaglutide has not been FDA-approved for weight loss or any other indication. Individual results will vary. This compounded formulation is not affiliated with, endorsed by, reviewed by, or intended to replace any FDA-approved product manufactured by Novo Nordisk. EOS Health and its pharmacy partners have no affiliation with Novo Nordisk.
Compounded Semaglutide is a once-weekly injectable that acts on the GLP-1 receptor, a hormone pathway involved in appetite and digestion. It is the lower-cost of the two GLP-1 options at EOS Health, and is prescribed for weight management when a U.S.-licensed clinician determines it is appropriate.
One-hormone mechanism: Semaglutide acts on the GLP-1 receptor, a pathway involved in satiety signaling and gastric emptying.
Appetite and fullness: Acts on the signals that regulate hunger and how long you feel full after eating.
Blood sugar regulation: Influences insulin and glucagon signaling as part of how the medication acts on metabolism.
Once-weekly dosing: One subcutaneous injection per week. No daily pills.
Clinician-supervised: A U.S.-licensed clinician reviews your intake, sets your starting dose, and stays reachable throughout treatment.